Clinical trials: Controlled Hypertension
Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)
Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension
The primary purpose of this study is to investigate the safety and efficacy of bilateral DWT in subjects with POAG or OHT compared to active and sham controls.
- Trial name
- NCT02226094
- Testing
- DWT device dose A, Ellex Tango SLT machine, DWT device dose B
- Where
- 2 sites in Philippines
- Volunteers
- 35 people
- Sponsor
- OcuTherix, Inc.
Resistant Hypertension, Difficult to Control Hypertension
Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects
A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening.
- Trial name
- DTC/RHS (NCT05247528)
- Testing
- MANP
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- E-Star BioTech, LLC
Glaucoma, Open-Angle, Ocular Hypertension
Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety
The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved…
- Trial name
- NCT05857267
- Testing
- Dorzolamide / Timolol Ophthalmic Solution, dorzolamide/timolol
- Where
- 6 sites in Argentina
- Volunteers
- 84 people
- Sponsor
- Laboratorios Poen
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension, Pulmonary
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
- Trial name
- SALTO (NCT04175600)
- Testing
- Selexipag, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor
- Where
- 116 sites in United States, Australia and 30 more
- Volunteers
- 138 people
- Sponsor
- Actelion
Pre-Eclampsia
Evaluation of the Safety of Relaxin in Preeclampsia
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
- Trial name
- NCT00333307
- Testing
- recombinant human relaxin
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Hypertension, Dyslipidemia
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of DWJ1276
- Trial name
- NCT01764295
- Testing
- DWJ1276, Olmesartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）
This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics…
- Trial name
- NCT07368608
- Testing
- BEBT-701 Injection
- Where
- China
- Volunteers
- 340 people
- Sponsor
- BeBetter Med Inc
Hypertension
A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the…
- Trial name
- NCT00240474
- Testing
- Telmisartan 80 mg + hydrochlorothiazide 12.5 mg, Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
- Where
- 73 sites in Belgium, Denmark and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)
The goal of this study is to identify at least one safe and well tolerated dose of MK1809 that has similar pharmacokinetic qualities as 100 mg losartan.
- Trial name
- NCT01033318
- Testing
- MK1809, Comparator: Losartan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Hypertension, Pulmonary
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment…
- Trial name
- NCT00644605
- Testing
- sildenafil
- Where
- 68 sites in United States, Australia and 21 more
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy.
- Trial name
- NCT05975905
- Testing
- Dose A KER-012, Dose B KER-012, Dose C KER-012
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 113 people
- Sponsor
- Keros Therapeutics, Inc.
Glaucoma
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost.
- Trial name
- NCT01060579
- Testing
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Where
- 18 sites in United States
- Volunteers
- 217 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
- Trial name
- NCT00219024
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 2,775 people
- Sponsor
- Novartis
Hypertension, Metabolic Syndrome
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
- Trial name
- STAR (NCT00234858)
- Testing
- trandolapril/verapamil, (Hyzaar) losartan/hydrochlorothiazide
- Volunteers
- 280 people
- Sponsor
- Abbott
Hypertension
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
- Trial name
- NCT00770861
- Testing
- Nebivolol
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 277 people
- Sponsor
- Forest Laboratories
Hypertension
Corever in the Treatment of Hypertension
The study primarily aims to compare the effects of two doses of Corever with placebo in patients with hypertension.
- Trial name
- NCT02432937
- Testing
- Corever
- Where
- 8 sites in Taiwan
- Volunteers
- 134 people
- Sponsor
- TSH Biopharm Corporation Limited